1218 Chinese platform strategy
BioRender

Product Development

Chinese biotechs test the waters of novel technology platforms

Few platform companies are attracting top funding in China — at least not yet

Few platform companies are attracting top funding in China, but as the Chinese biotech sector evolves, it’s sampling new technologies through product licensing deals.

Dec 19, 2020 | 2:11 AM GMT

The Chinese biotechs attracting the most funding are accessing a growing number of innovative products through licensing deals, but so far, few have taken on the risk of developing technology platforms in-house. That picture could soon change. 

BioCentury’s analysis of the 97 Chinese biotechs that have raised over $100 million in venture funding

Read the full 1076 word article

How to gain access

Continue reading with a
two-week free trial.